Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
There is evidence of a different response to treatment with regard to the primary tumor localization (right-sided or left-sided) in patients with metastatic colorectal cancer (mCRC). We analyzed the different outcomes and biomolecular characteristics in relation to tumor localization in 122 of the 370 patients with metastatic colorectal cancer enrolled onto the phase III prospective multicenter “Italian Trial in Advanced Colorectal Cancer (ITACa)”, randomized to receive first-line chemotherapy (CT) or CT plus bevacizumab (CT + B). RAS and BRAF mutations; baseline expression levels of circulating vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), cyclooxygenase-2 (COX2), ephrin type-B receptor 4 (EPHB4), hypoxia-inducible factor 1-alpha (HIF-1α), lactate dehydrogenase (LDH), and high-sensitivity C reactive protein (hs-CRP); and inflammatory indexes such as the neutrophil-to-lymphocyte ratio, platelet-lymphocyte rate and systemic immune-inflammation index were evaluated. Patients with right-sided tumors showed a longer median progression-free survival in the CT + B arm than in the CT group (12.6 vs. 9.0 months, respectively, p = 0.017). Baseline inflammatory indexes were significantly higher in left-sided tumors, whereas eNOS and EPHB4 expression was significantly higher and BRAF mutation more frequent in right-sided tumors. Our data suggest a greater efficacy of the CT + B combination in right-sided mCRC, which might be attributable to the lower inflammatory status and higher expression of pro-angiogenic factors that appear to characterize these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3797 · Cited by 709 · cited 2×
“However, EGFR inhibitor activity has been shown to be higher in left-sided tumors even when all RAS wt patients are considered [3,13], suggesting that other molecular mechanisms such as higher EGFR ligand expression (epiregulin and amphiregulin) might be involved in left-sided lesions [2,22].”
BackgroundHolch, J. W., Ricard, I., Stintzing, S., Modest, D. P., & Heinemann, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.007 · Cited by 534
Cited by
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123733 · Cited by 262
“In particular, higher expression levels of cyclooxygenase-2 (COX2), ephrin type-B receptor 4 (EPHB4), and endothelial nitric oxide synthase (eNOS) were observed in right-sided with respect to left-sided tumors, whereas baseline inflammatory indexes such as neutrophil-to-lymphocyte ratio, platelet-lymphocyte rate, and…”
BackgroundSelf-citationRecent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“In front-line treatment for mCRC, anti-VEGF therapy was shown to be comparable with anti-EGFR therapy when either was combined with chemotherapy [126], and while some previous studies indicated that chemotherapy was more effective in right-sided CRC [127], no side dependence was detected.”
Result
Metadata
- Authors
- Ulivi, P., Scarpi, E., Chiadini, E., Marisi, G., Valgiusti, M., Capelli, L., Casadei Gardini, A., Monti, M., Ruscelli, S., Frassineti, G., Calistri, D., Amadori, D., & Passardi, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-06-09
- Volume
- 18
- Issue
- 6
- Pages
- 1240
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2623055186
- Cited by
- 42
- References
- 2
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. https://app.cochat.ai/papers/10.3390/ijms18061240
- The paper
- Ulivi, P., Scarpi, E., Chiadini, E., Marisi, G., Valgiusti, M., Capelli, L., Casadei Gardini, A., Monti, M., Ruscelli, S., Frassineti, G., Calistri, D., Amadori, D., & Passardi, A. (2017). Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18061240
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.